<DOC>
	<DOCNO>NCT01145079</DOCNO>
	<brief_summary>Drug-eluting stent ( DES ) , markedly reduce neointimal hyperplasia stent implantation compare bare-metal stent ( BMS ) , improve angiographic clinical outcome complex lesion patient high risk . However , currently , fatal event related stent thrombosis still occur major limitation use DES . Especially , late late thrombosis DES implantation uncommon life-threatening fatal complication present sudden death myocardial infarction ( MI ) cause heart failure . The powerful predictor stent thrombosis discontinuation clopidogrel . In consideration current data regard stent thrombosis clinical situation discontinuation antiplatelet , zotarolimus-eluting stent ( ZES ) [ Endeavor® , Medtronic Vascular , Santa Rosa , CA ] might anticipate safer DES long-term follow-up owe healthy endothelialization . Endeavor® stent consist zotarolimus , thin-strut , cobalt-chromium alloy stent platform ( DriverTM stent ; Medtronic Vascular , Santa Rosa , CA ) , phosphorylcholine coating . The ENDEAVOR II study demonstrate clinically statistically significant improvement study endpoint , include 47 percent reduction primary endpoint target vessel failure ( TVF ) . In addition , ENDEAVOR II trial show 0.5 percent rate stent thrombosis 30 day - late thrombosis beyond 30 day late stent malapposition . Because reendothelialization ZES implantation may occur within 3 month , 3-month dual antiplatelet therapy recommend many clinical trial real world practice . Shorter maintenance dual antiplatelet therapy might minimize risk stent thrombosis case discontinuation antiplatelet prevent waste medication bleed complication relate dual antiplatelet therapy . However , non-inferior superior data ZES consider circumstance . Therefore , investigator hypothesize ZES 3-month dual antiplatelet therapy may safe beneficial patient coronary artery disease follow-up DES , spite high late lumen loss . To test hypothesis , investigator perform multi-center , randomize , prospective trial aim demonstrate efficacy ZES versus DES patient coronary artery disease real world practice .</brief_summary>
	<brief_title>A New Strategy Regarding Discontinuation Dual Antiplatelet</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Coronary artery disease include stable angina , unstable angina , acute nonST elevation myocardial infarction acute ST elevation myocardial infarction Age 20 year old Patients typical chest pain evidence myocardial ischemia ( e.g. , stable , unstable angina , silent ischemia positive functional study reversible change electrocardiogram ( ECG ) consistent ischemia Patients sign informed consent Lesion stent length ACS DM subgroup : Length single lesion &lt; 24 mm , Summation total length insert DES 3 vessel &lt; 60 mm Lesion stent length ACS DM subgroup : Length single lesion &lt; 24 mm , Summation total length insert DES 3 vessel &lt; 60 mm Lesion stent length long lesion subgroup : Length single stent per single lesion &gt; 28 mm , Summation total length insert DES 3 vessel ≤ 90 mm , Possible overlap stent Lesion stent length short lesion subgroup : Length single lesion &lt; 24 mm , Summation total length insert DES 3 vessel &lt; 60 mm Significant coronary artery stenosis ( &gt; 50 % visual estimate ) consider coronary revascularization stent implantation Reference vessel diameter 2.5 4.0 mm operator assessment Lesion success ( 30 % less residual stenosis visual assessment entire stent length , TIMI3 flow NHLBI type B peristent dissection Contraindication antiplatelet agent &amp; bleed history within prior 3 month Known hypersensitivity contraindication follow medication : Heparin , Aspirin , Clopidogrel , limus related drug Prior history follow presentation : Cerebral vascular accident ( include transient ischemic attack , Peripheral artery occlusive disease , Thromboembolic disease , Stent thrombosis Severe hepatic dysfunction ( 3 time normal reference value ) Significant renal dysfunction ( Serum creatinine &gt; 2.0 mg/dl ) Significant leukopenia , neutropenia , thrombocytopenia , anemia , know bleed diathesis Cardiogenic shock LVEF &lt; 40 % Pregnant woman woman potential childbearing Life expectancy 3 year Overlapped DESs ( long lesion subgroup possible overlap ) Left main disease require PCI Bifurcation lesion 2stent technique Target lesion instent restenosis stented segment DES BMS Lesions chronic total occlusion History PCI DES Instent restenosis lesion</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>